Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
The company impresses investors, but money’s running short.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
